World Health Organization Issues Alert Over Severe Shortage of Obesity Jabs

Under 10% of people that would benefit from obesity jabs including Wegovy are able to get them, caution the World Health Organization as it issues its first advice on the medications.

Given in excess of 1,000,000,000 people worldwide now obese, it is urging broader and more equitable access to GLP-1 medication.

Per projections, over two billion could be obese by 2030 if no action is taken.

"Our latest guidance affirms that obesity is a long-term condition that can be addressed with holistic and ongoing treatment," said WHO director-general Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and logistical bottlenecks are key obstacles to broad availability to the jabs that can help people shift considerable weight, notes the agency.

Weight-Loss Drug Shortage

Even in the present most favorable case, the production of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of eligible patients, as stated by the WHO.

The recommendation encourages nations and manufacturers to widen availability, via measures like patent sharing.

A patent on the active ingredient – the core component of a leading brand – is scheduled to end in several countries in 2026.

How Weight-Loss Jabs Function

These medications imitate a biological compound to reduce digestion speed, reduce hunger and enhance feelings of fullness so users reduce food intake.

Patients commonly see weight reduction in the initial weeks of beginning the weekly injections.

Research suggests users may put most of the weight back on after a year of discontinuing the medication, when their typical food cravings come back.

Being above a healthy weight increases your risk for contracting diseases, like diabetes, heart disease, stroke, and certain malignancies.

Excess weight impacts people in all nations and was associated with millions of fatalities worldwide in 2024, according to the WHO.